Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01811498 : Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Eligibility
Criteria for Inclusion:

- Male or female patients of =18 years of age.

- Patients with documented histologic diagnosis of glioblastoma multiforme (newly
diagnosed)

- Patients must have at least one confirmed and evaluable tumor site.*

*A confirmed tumor site is one which is biopsy-proven. NOTE: Radiographic procedures
(e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been
performed within three weeks of treatment on this research study.

- Patients must have a Karnofsky performance status =70% (or the equivalent ECOG level
of 0-2) and an expected survival of = three months.

- Patients must agree to use a medically effective method of contraception during and
for a period of three months after the treatment period. A pregnancy test will be
performed on each premenopausal female of childbearing potential immediately prior to
entry into the research study.

Criteria for Exclusion:

- Previous treatment with Bevacizumab.

- Women who are pregnant or lactating.

- Women of childbearing potential and fertile men who decline to use effective
contraception during and for a period of three months after the treatment period.

- Patients with significant intercurrent medical or psychiatric conditions that would
place them at increased risk or affect their ability to receive or comply with
treatment or post-treatment clinical monitoring.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01811498      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740